Phaseline

Targets › PGRN

PGRN: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Nov 2026.

Open in Phaseline: the race on PGRN, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
A&G PharmaceuticalAG-01
anti-Progranulin/GP88 monoclonal antibody
PGRNPhase 1Triple Negative Breast CancerNov 2026

Conditions

Triple Negative Breast Cancer (1)

Modalities

small molecule (1)

Companies

A&G Pharmaceutical (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.